'Strong guardrails key to GenAI success'

INDEGENE, a Bengaluru-based healthtech company is developing capabilities in generative AI to help pharma companies deliver drugs faster to patients, while bringing down the costs of sales & marketing for them.

- INTERVIEW: TARUN MATHUR, CTO, INDEGENE

The company offers a range of services including digital solutions, commercialisation strategies, and support for clinical trials, safety, and regulatory operations. In Q1FY26, Indegene maintained a trajectory of stable and profitable growth, recording ₹760.8 crore in revenues compared to ₹676.5 crore during Q1FY25.

Tarun Mathur, CTO at Indegene speaks to Sudhir Chowdhary on how pharma companies can learn to scale GenAI and address the industry's unique challenges. Excerpts:

Has GenAI adoption in pharma reached a tipping point? Pharma has a diverse range of use cases where GenAI-backed transformation of existing processes could yield valuable business as well as patient, caregiver, and regulatory outcomes. And multiple use cases across the pharma life cycle have progressed beyond early experiments and have either scaled into production or are in the process of doing so.

That said, enterprises continue to evaluate the art of possibility and identify more opportunities. Experimentation remains a part of continuous innovation. Pharma leaders are figuring out how to scale and facilitate the change management that comes with GenAI adoption.